Investors

  • TSX.V: DXD
  • OTCQB: TDSGF FSE: 3D0

CONTACT

Investor Relations
E investors@3dsignatures.com
604 428 8842

Stock Information (as of May 8, 2017)

Issued and Outstanding Shares 53,408,780
Warrants 7,044,814
Options 5,179,081
Fully Diluted Shares 65,632,675
Board and
Management Ownership
35%

INVESTMENT HIGHLIGHTS

DISRUPTIVE TECHNOLOGY

Proprietary 3D imaging technology could represent a major medical advancement in patient diagnosis, treatment and the development of companion diagnostics to personalize patient treatment.

ATTRACTING INDUSTRY MAJORS

Highly promising and unconventional software platform is already attracting attention from multinational healthcare companies relatively early in the product development process.

EXCEPTIONAL TIMING AHEAD OF IMPORTANT CATALYSTS

Steady stream of positive news flow expected including talent acquisition, clinical trial progress and new business developments

SOFTWARE AS A SERVICE (SaaS) MODEL

Building a highly scalable SaaS based business with high margins and low overhead. Proprietary software never leaves the Company’s server while raw digital data can be collected and analyzed from partner labs located around the world.

EXPERT TEAM WITH SUCCESSFUL TRACK RECORD IN BIOMEDICAL MARKET

Accomplished leadership with the ability to develop and commercialize new products and secure strategic partnerships.

STRONG FISCAL MANAGEMENT

Drive growth through strategic allocation of capital. Control expenses through sensible fiscal management and streamlined operations.

FINANCIALS

LICENSING

3D Signatures is actively seeking potential licensing opportunities. To discuss a partnering or collaboration opportunity, please submit your query to info@3dsignatures.com.